Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Jan 22, 2024 (filed on Jan 24, 2024)Insider Name:Mehalik DaniellaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:70,000Price:--
-
Jan 22, 2024 (filed on Jan 24, 2024)Insider Name:Mehalik DaniellaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Dec 19, 2023 (filed on Dec 19, 2023)Insider Name:Mehalik DaniellaOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Sep 25, 2023 (filed on Sep 25, 2023)Insider Name:Shoemaker ShannonOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Sep 21, 2023 (filed on Sep 25, 2023)Insider Name:Shoemaker ShannonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Sep 21, 2023 (filed on Sep 25, 2023)Insider Name:Shoemaker ShannonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Aug 17, 2023 (filed on Aug 22, 2023)Insider Name:Weisenhoff MichaelOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,000Price:--
-
Aug 17, 2023 (filed on Aug 21, 2023)Insider Name:Doucot Charles MOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,700Price:$4.66
-
Aug 17, 2023 (filed on Aug 21, 2023)Insider Name:Hullinger BrianOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Aug 17, 2023 (filed on Aug 21, 2023)Insider Name:Hullinger BrianOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
Filings by filing date
-
Jan 22, 2024 (filed on Jan 24, 2024)Insider Name:Mehalik DaniellaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:70,000Price:--
-
Jan 22, 2024 (filed on Jan 24, 2024)Insider Name:Mehalik DaniellaOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Dec 19, 2023 (filed on Dec 19, 2023)Insider Name:Mehalik DaniellaOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Sep 21, 2023 (filed on Sep 25, 2023)Insider Name:Shoemaker ShannonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:80,000Price:--
-
Sep 21, 2023 (filed on Sep 25, 2023)Insider Name:Shoemaker ShannonOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:40,000Price:--
-
Sep 25, 2023 (filed on Sep 25, 2023)Insider Name:Shoemaker ShannonOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Aug 17, 2023 (filed on Aug 22, 2023)Insider Name:Weisenhoff MichaelOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,000Price:--
-
Aug 17, 2023 (filed on Aug 21, 2023)Insider Name:Doucot Charles MOwnership Type:Direct OwnershipSecurities:Common Stock, $.005 Par ValueNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,700Price:$4.66
-
Aug 17, 2023 (filed on Aug 21, 2023)Insider Name:Hullinger BrianOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:200,000Price:--
-
Aug 17, 2023 (filed on Aug 21, 2023)Insider Name:Hullinger BrianOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:100,000Price:--
News
Biz Brief
Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 125 Nagog Park Ste 200 ACTON MA 01720-3451 |
Tel: | N/A |
Website: | https://www.psychemedics.com |
IR: | See website |
Key People | ||
Brian Hullinger President, Chief Executive Officer, Director | Daniella Mehalik Vice President - Finance, Treasurer | Shannon Shoemaker Chief Revenue Officer |
Business Overview |
Psychemedics Corporation is a hair drug testing company. The Company provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The Company customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The Company markets its corporate drug testing services through its own sales force, distributors, and partners. It markets its home drug testing service, PDT-90, through the Internet. |
Financial Overview |
For the fiscal year ended 31 December 2023, Psychemedics Corp. revenues decreased 12% to $22.1M. Net loss increased from $1.1M to $4.2M. Revenues reflect Testing segment decrease of 14% to $18.7M, Shipping Collection Hair segment decrease of 5% to $3.3M, United States segment decrease of 13% to $21.2M. Higher net loss reflects Other General & Administrative increase of 23% to $6.4M (expense). |
Employees: | 116 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $13.20M as of Dec 31, 2023 |
Annual revenue (TTM): | $22.10M as of Dec 31, 2023 |
EBITDA (TTM): | -$1.19M as of Dec 31, 2023 |
Net annual income (TTM): | -$4.15M as of Dec 31, 2023 |
Free cash flow (TTM): | -$1.64M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 5,805,611 as of Mar 25, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |